How it works:
Pomalidomide is an immunomodulatory agent derived from thalidomide, with anti-cancer and anti-angiogenic activity. It inhibits malignant cell growth, enhances T-cell and NK cell function, and blocks new blood vessel formation in tumour tissue.
Recommended for:
Adults with multiple myeloma
Patients whose disease progressed after treatment with lenalidomide and bortezomib
Individuals needing supportive therapy in combination with dexamethasone
Those who have undergone at least two previous therapies without sustained response
Relapsed or refractory multiple myeloma in adults who have received at least two prior lines of therapy including lenalidomide and bortezomib
The drug is taken orally at the same time each day for 21 days of a 28-day cycle, followed by a 7-day rest period. Typically used with dexamethasone. Dosage is individually determined by the physician based on the patient's condition and treatment plan.
Hypersensitivity to pomalidomide or excipients
Pregnancy and lactation
Patients under 18 years
Severe hepatic or renal impairment
Anaemia, neutropenia, thrombocytopenia
Infections including pneumonia
Fatigue, weakness
Constipation, diarrhoea, nausea
Elevated liver enzymes
Rash, skin reactions
Thromboembolism
Headache, dizziness
